Regulus Gets License From NYU

3/30/11

Regulus Therapeutics, the San Diego-based developer of microRNA therapies, said today that it has obtained exclusive rights from New York University to develop treatments against a couple of microRNA targets (miR-33a and miR-33b) which are thought to have potential to affect athersclerosis and metabolic syndrome. Financial terms of the license weren’t disclosed.

By posting a comment, you agree to our terms and conditions.